search
Back to results

Impact of a One-month Long Detoxification Diazepam Treatment on Early Alcohol Relapse (DIAMA)

Primary Purpose

Alcoholism

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Diazepam
Sponsored by
University Hospital, Lille
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Alcoholism focused on measuring Alcohol-dependence, Relapse, Detoxification, Diazepam, Benzodiazepines, Anxiety

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • DSM-IV-Tr criteria for alcohol dependence
  • Diazepam-based outpatient detoxification procedure started 5 days prior to inclusion

Exclusion Criteria:

  • contraindication for outpatient detoxification
  • occurrence of delirium tremens or seizures during the pre-inclusion period
  • contraindication for using diazepam
  • any other DSM-IV-TR criteria for substance abuse or dependence in the preceding year (except from tobacco)
  • concurrent axis-I psychiatric disorder
  • concurrent neurological pathology or cognitive impairment
  • concurrent social risk, i.e., homelessness or social isolation
  • liver failure, cancer, or significant breathing disorder

Sites / Locations

  • Department of Addiction Medicine
  • Outpatient Addiction Center "CSAPA - Le Pari"

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

AD = "as-usual diazepam"

PD = "prolonged diazepam"

Arm Description

Diazepam treatment duration will not exceed 10 days (commonly recommended duration for alcohol detoxification).

Diazepam will be slowly tapered to be stopped at day 30

Outcomes

Primary Outcome Measures

Rate of relapse in alcohol drinking
Proportion of patients who will have reported any alcohol drinking over the three months following the beginning of the detoxification procedure (using the alcohol timeline follow-back method).

Secondary Outcome Measures

Occurrence of adverse events
Rate of relapse in heavy drinking
Proportion of patients who will have reported at least one heavy drinking day, i.e., ≥ 50 g of alcohol in a day, over the first month and the three month following the beginning of the detoxification procedure (using the alcohol timeline follow-back method).
Ratio of drinking days/heavy drinking days
Level of self-reported anxiety
Score of self-reported anxiety using the State-Trait Anxiety Inventory
Level of clinician-assessed anxiety
Score of anxiety using the Hamilton Anxiety Rating Scale
Level of alcohol craving
Level of alcohol craving using the Obsessive-Compulsive Drinking Scale
Average weekly alcohol consumption

Full Information

First Posted
September 15, 2014
Last Updated
September 14, 2016
Sponsor
University Hospital, Lille
search

1. Study Identification

Unique Protocol Identification Number
NCT02242955
Brief Title
Impact of a One-month Long Detoxification Diazepam Treatment on Early Alcohol Relapse
Acronym
DIAMA
Official Title
Impact of a One-month Long Detoxification Diazepam Treatment on Early Alcohol Relapse
Study Type
Interventional

2. Study Status

Record Verification Date
September 2016
Overall Recruitment Status
Completed
Study Start Date
July 2014 (undefined)
Primary Completion Date
July 2016 (Actual)
Study Completion Date
July 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Lille

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Alcohol-dependence is a medical condition that can lead to the occurrence of an alcohol withdrawal syndrome (AWS) in case of alcohol drinking cessation. Diazepam is the reference medication for preventing or treating AWS. The recommended average diazepam treatment duration is usually around one week, and this duration is generally not considered to impact the subsequent relapse rate in alcohol drinking. However, several previous studies have found that patients experienced frequent anxious symptoms during the weeks following detoxification. Such symptoms may foster early relapse in alcohol drinking. Furthermore, it has been suggested that this anxiety could pertain to late withdrawal symptoms. The DIAMA study hypothesizes that extending the diazepam detoxification treatment to one month can significantly reduce the cumulated relapse rate in alcohol drinking over the three following months.
Detailed Description
inclusion at Day 5 of the outpatient alcohol detoxification procedure randomization in two arms: 1) "10 day - diazepam"; and 2) "30 day - diazepam" tapering of diazepam over the 10 days following the beginning of the detoxification procedure in the first arm; tapering of diazepam over the 30 days following the beginning of the detoxification procedure in the second arm. 3-month-long follow-up after detoxification. Objective of maintaining abstinence from alcohol. No use of additional anticraving drug. Standardised psychotherapeutic support based on the BRENDA model. Longitudinal recording of alcohol consumption using the Alcohol Timeline Follow-Back method. Assessment of craving (Obsessive-Compulsive Drinking Scale) and anxiety (State-Trait Anxiety Inventory; Hamilton Anxiety Rating Scale) at Days 5 (baseline), 15, 30, 60 and 90 (final assessment).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alcoholism
Keywords
Alcohol-dependence, Relapse, Detoxification, Diazepam, Benzodiazepines, Anxiety

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
26 (Actual)

8. Arms, Groups, and Interventions

Arm Title
AD = "as-usual diazepam"
Arm Type
Active Comparator
Arm Description
Diazepam treatment duration will not exceed 10 days (commonly recommended duration for alcohol detoxification).
Arm Title
PD = "prolonged diazepam"
Arm Type
Experimental
Arm Description
Diazepam will be slowly tapered to be stopped at day 30
Intervention Type
Drug
Intervention Name(s)
Diazepam
Intervention Description
40 mg per day.
Primary Outcome Measure Information:
Title
Rate of relapse in alcohol drinking
Description
Proportion of patients who will have reported any alcohol drinking over the three months following the beginning of the detoxification procedure (using the alcohol timeline follow-back method).
Time Frame
at 3 months
Secondary Outcome Measure Information:
Title
Occurrence of adverse events
Time Frame
Over the first month, at 3 months
Title
Rate of relapse in heavy drinking
Description
Proportion of patients who will have reported at least one heavy drinking day, i.e., ≥ 50 g of alcohol in a day, over the first month and the three month following the beginning of the detoxification procedure (using the alcohol timeline follow-back method).
Time Frame
at 1 month; at 3 months
Title
Ratio of drinking days/heavy drinking days
Time Frame
over the first month, at 3 months
Title
Level of self-reported anxiety
Description
Score of self-reported anxiety using the State-Trait Anxiety Inventory
Time Frame
at 1 month; at 3 months
Title
Level of clinician-assessed anxiety
Description
Score of anxiety using the Hamilton Anxiety Rating Scale
Time Frame
at 1 month; at 3 months
Title
Level of alcohol craving
Description
Level of alcohol craving using the Obsessive-Compulsive Drinking Scale
Time Frame
at 1 month; at 3 months
Title
Average weekly alcohol consumption
Time Frame
at 1 month; at 3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: DSM-IV-Tr criteria for alcohol dependence Diazepam-based outpatient detoxification procedure started 5 days prior to inclusion Exclusion Criteria: contraindication for outpatient detoxification occurrence of delirium tremens or seizures during the pre-inclusion period contraindication for using diazepam any other DSM-IV-TR criteria for substance abuse or dependence in the preceding year (except from tobacco) concurrent axis-I psychiatric disorder concurrent neurological pathology or cognitive impairment concurrent social risk, i.e., homelessness or social isolation liver failure, cancer, or significant breathing disorder
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Benjamin ROLLAND, MD, PhD
Organizational Affiliation
University Hospital of Lille (CHU Lille), France
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Addiction Medicine
City
Lille
ZIP/Postal Code
59037
Country
France
Facility Name
Outpatient Addiction Center "CSAPA - Le Pari"
City
Lille
ZIP/Postal Code
59037
Country
France

12. IPD Sharing Statement

Learn more about this trial

Impact of a One-month Long Detoxification Diazepam Treatment on Early Alcohol Relapse

We'll reach out to this number within 24 hrs